Loading...
•
Mar 31, 2021
Leap Therapeutics Q1 2021 Earnings Report
Leap Therapeutics reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Leap Therapeutics reported a net loss of $9.1 million for the first quarter of 2021, compared to a net loss of $7.2 million for the same period in 2020. License revenues were $0.4 million for both the first quarter of 2021 and 2020.
Net loss was $9.1 million for the first quarter 2021, compared to $7.2 million for the same period in 2020.
License revenues were $0.4 million for each of the first quarter 2021 and 2020.
Research and development expenses were $6.8 million for the first quarter 2021, compared to $4.6 million for the same period in 2020.
Cash and cash equivalents totaled $43.5 million at March 31, 2021.
Forward Guidance
This press release contains forward-looking statements within the meaning of the securities act of 1933 and the securities exchange act of 1934, which involve risks and uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...